Literature DB >> 31146821

Monitoring Emerging Data From the COMPASS Trial of an Antithrombotic Agent.

John A Cairns1, John W Eikelboom2, Olga Shestakovska2, Salim Yusuf2, David DeMets3.   

Abstract

Keywords:  cardiovascular events; clinical trial stopping guidelines; clinical trials; data monitoring; major bleeding

Year:  2019        PMID： 31146821     DOI： 10.1016/j.jacc.2019.03.479

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN： 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  2 in total

1.  Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease.

Authors:  Gilles R Dagenais; Leanne Dyal; Jacqueline J Bosch; Darryl P Leong; Victor Aboyans; Scott D Berkowitz; Deepak L Bhatt; Stuart J Connolly; Keith A A Fox; Eva Muehlhofer; Jeffrey L Probstfield; Petr Widimsky; Bernhard R Winkelmann; Salim Yusuf; John W Eikelboom
Journal:  Heart       Date:  2021-05-21       Impact factor: 5.994

Review 2.  Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment.

Authors:  Hugo Ten Cate; Tomasz J Guzik; John Eikelboom; Henri M H Spronk
Journal:  Cardiovasc Res       Date:  2021-07-27       Impact factor: 10.787
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.